Skip to main content

Introducing ACTX 101, a Gene Therapy for Rett Using X Reactivation Technology

May 12, 2021

Traditional gene therapy delivers healthy genes to compensate for mutated ones. During this webinar you will learn about a novel gene therapy approach, ACTX-101 being developed for Rett Syndrome by Alcyone Therapeutics. Rather than deliver a gene, ACTX-101 is designed to reactivate the inactive X chromosome which includes the MECP2 gene. Dr. Sanchita Bhatnagar and Dr. Kathrin Meyer are the scientists behind ACTX-101. They are joined by Dr. Bryn Martin, of Alcyone Therapeutics. Watch and learn about this exciting new strategy to attack Rett Syndrome.


More Resources

Our Plan for a Cure: MECP2 Reactivation

Rett News About Alcyone Therapeutics